hs-1

Hs-1, an antimicrobial peptide, exhibits 80% protection against the Dengue-2 virus [1].

HS-173 is an effective PI3Kα inhibitor (IC50: 0.8 nM).

HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model

YHS-12, a ionizable cationic lipid (pKa = 6.506), has been utilized both in vitro and in vivo for delivering siRNA and mRNA via lipid nanoparticles (LNPs). These LNPs comprise YHS-12 and a targeting peptide CRVLRSGSC aimed at macrophages, encapsulating chimeric antigen receptor mRNA targeted at methicillin-resistant Staphylococcus aureus (MRSA) and siRNA against caspase-11. The LNPs have enhanced the phagocytic efficiency against MRSA in RAW 264.7 macrophages and primary murine bone marrow-derived macrophages (BMDMs). Administered intravenously, these LNPs have reduced bacterial load in the bloodstream and increased survival rates in a sepsis model in cyclophosphamide-induced immunosuppressed mice.

CHS-111 is a benzyl indazole compound that inhibits superoxide anion (O(2)(-)) generation and reduces fMLP-stimulated PLD activity (IC(50) 3.9±1.2μM). It inhibits the interaction of PLD1 with ADP-ribosylation factor (Arf) 6 and Ras homology (Rho) A, and reduces the membrane recruitment of RhoA in fMLP-stimulated cells.

HS-1371 is a novel kinase inhibitor of receptor-interacting protein kinase 3 (RIP3) with an IC50 of 20.8 nM.

HS-152 is a novel reversible inhibitor of smurf1, directly targeting the catalytic activity of smurf hect domains, significantly blocking auto-ubiquitination and the transfer of ubiquitin from hect domain to the substrates to form isopeptide bond

CHS-114 (SRF-114) is a fully human IgG1 antibody targeting the (CCR8) receptor. It shows potential for research in head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can be referred to as HumanIgG1kappa, Isotype Control.

Darbufelone (CI-1004) is a non-competitive dual inhibitor of PGF2α and LTB4. Dabfilon effectively inhibits PGHS-2 with a Ki of 10 μM and IC50s of 0.19 μM and 20 μM for PGHS-2 and PGHS-1.

Darbufelone mesylate (CI-1004 mesylate) inhibited PGF2α and LTB4 in cells and demonstrated IC50 values of 0.19 μM for PGHS-2 and 20 μM for PGHS-1.

Tenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.

(R,1R)-Tenofovir amibufenamide ((R,1R)-HS-10234) is an orally administered Tenofovir prodrug with antiviral activity. Tenofovir is a nucleotide reverse transcriptase inhibitor.

Polyethylene glycol 12-hydroxystearate (Solutol HS-15) is a permeability enhancer.

Almonertinib (HS-10296) is an inhibitor specifically targeting EGFR activation mutations and the resistant EGFR T790M mutation, exhibiting limited activity against wild-type EGFR.

Almonertinib hydrochloride (HS-10296 hydrochloride) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.

Almonertinib mesylate is an irreversible inhibitor of EGFR tyrosine kinase with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate can be used in the non-small cell lung cancer studies.

ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist with EC50 values of 7.12 nM and 517 nM for hS1P1 and hS1P3, respectively.

Ceralifimod (ONO-4641) is a potent agonist for sphingosine 1-phosphate receptors 1 and 5 (EC50s: 27.3, 334 pM for human S1P receptor 1 and 5).

Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.

KHS101 is a novel inhibitor of transforming acidic coiled-coil protein 3 (TACC3). It is a selective inducer of neuronal differentiation.

KHS101 is a TACC3 inhibitor and can selectively induce a neuronal differentiation phenotype.

BAP2 is a novel inhibitor of protein disulfide isomerase (PDI).

HS148 is a selective inhibitor of DAPK3 (death-associated protein kinase 3), with a Ki value of 119 nM. Inhibition of DAPK3 by HS148 has been shown to reduce the progression of gastric cancer by activating the ULK1-dependent pathway, which is implicated in cellular autophagy and tumor suppression mechanisms.

AMG131 (CHS 131) , is a novel, non-thiazolidinedione (TZD), selective peroxisome proliferator-activated receptor (PPAR)gamma modulator, which can be used for the treatment of type 2 diabetes mellitus (non-insulin dependent diabetes)